Long-term monitoring of adults with type I interferon autoantibodies or genetic interferon defects
Official title: Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06762002 · Data updated 2026-11-12
We will follow adults who have autoantibodies to type I interferons or genetic defects that impair interferon responses to see if they develop more infections or autoimmune problems and how antibody levels change over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 9 sites (Lille and 8 other locations) |
| Status | Recruiting |
| Started | April 9, 2025 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT06762002 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with documented type I interferon–neutralizing autoantibodies or a genetic defect impairing type I IFN production or response, who can give informed consent and are covered by French social security, are ideal candidates.
✕Probably not a fit
People without such autoantibodies or genetic defects, those with a life expectancy under one year, or those enrolled in an interventional pharmacological trial are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective national cohort will enroll adults known to carry neutralizing autoantibodies against type I interferons or to have inherited defects affecting type I IFN production or signaling. Participants will provide serial blood samples and undergo clinical follow-up to record infectious and autoimmune events and to measure the kinetics and neutralizing activity of the autoantibodies. The study is observational and non-interventional, conducted at specialist centers in Lille, Lyon and Montpellier, France. Data will be used to improve understanding of risk patterns and to inform prevention and management strategies for affected individuals.
Why it matters
Potential benefit: If successful, the project could help identify who is at higher risk for severe infections or autoimmunity and guide prevention and personalized care.
How similar studies have gone: Previous observational work identified type I IFN–neutralizing autoantibodies in about 15% of severe COVID-19 cases and inborn errors affecting IFN responses in about 4%, but prospective longitudinal follow-up of these patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years * History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI) * Affiliated to social security * Written informed consent Exclusion Criteria: * Participation to an interventional clinical trial on a pharmacological treatment * Clinical condition leading to life expectancy less than 1 year * Subject to a legal protection measure (safeguard of justice, curatorship, tutorship) * Individuals deprived of freedom
Where it's running
-
Cic Lille
Lille, France Recruiting -
Lyon Hcl
Lyon, France Recruiting -
Cic Montpellier
Montpellier, France Recruiting -
Cic Bichat
Paris, France Recruiting -
Cic Creteil
Paris, France Recruiting -
Cic La Salpetriere
Paris, France Recruiting
Show 3 more locations
-
Cic Necker
Paris, France Recruiting -
Cic St Louis
Paris, France Recruiting -
Cic Tours
Tours, France Recruiting
Study contacts
- Study coordinator: Xavier-Marie DUVAL, PU-PH
- Email: xavier.duval@aphp.fr
- Phone: 01 40 25 71 48
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
What the Mayo Clinic is learning from blood clot tests in allergic reactions
This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.
-
HSCT outcomes in children at Ramathibodi Hospital
This study tests how hematopoietic stem cell transplantation works in pediatric patients with blood diseases, cancers, and other conditions at Ramathibodi Hospital.
-
Does having allergic parents raise the chance of bronchiolitis in babies by 12 months?
We’re testing if infants with at least one allergic parent are more likely to have bronchiolitis by 12 months compared to infants whose parents have no allergies.
-
Dietitian-led nutrition care in hospital wards
This trial tests whether having clinical dietitians lead nutritional care for adults in medical wards improves meals, well‑being, and reduces hospital stay and costs.
-
Using alpha-gal KO pork to see if it reduces reactions in people with Alpha-gal Syndrome
This study tests whether eating pork that lacks the alpha-gal allergen lowers reaction risk for people with Alpha-gal Syndrome, using a crossover design where each participant tries both KO and wild-type pork on separate days.
-
AOC 1044 in Duchenne Muscular Dystrophy with Exon 44 Skipping
This study tests whether intravenous AOC 1044 helps boys with Duchenne muscular dystrophy caused by mutations amenable to exon 44 skipping.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.